President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future anticipated developments. Plus, discussing the company's OX40 antagonist for atopic dermatitis that will have key healthy volunteer proof of concept data in the third quarter of this year.
View all episodes
By BiotechTV
5
44 ratings
President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future anticipated developments. Plus, discussing the company's OX40 antagonist for atopic dermatitis that will have key healthy volunteer proof of concept data in the third quarter of this year.
30,648 Listeners
1,892 Listeners
1,092 Listeners
325 Listeners
6,084 Listeners
61 Listeners
9,911 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
511 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners